In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts

Z. G. Tian, D. L. Longo, S. Funakoshi, O. Asai, D. K. Ferris, William J Murphy, W. J. Murphy

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

CD30 is a M(r) 120,000 surface antigen identified originally by the Ki-1 monoclonal antibody (rahAb) against primary and cultured Reed-Sternberg cells present in Hodgkin's disease and anaplastic large-cell lymphomas (ALCLs). Examination of two ALCL cell lines (Karpas 299 and Michel) demonstrated cell surface expression of CD30. Incubation of these lymphomas with two anti-CD30 moAbs that recognize the ligand-binding site (M44 or HeFi-1) resulted in significant growth inhibition in vitro, with significant decreases in cell viability. Another anti-CD30 moAb, Ber-H2, which recognizes a determinant not involved in ligand binding, had no effect on ALCL growth in vitro. When these human ALCL lines were transferred i.v. into mice with severe combined immune deficiency, the mice developed extensive metastasis in the s.c., brain, or eye tissues. The treatment of mice with either M44 or HeFi-1 anti-CD30 moAbs resulted in significant increases in survival, with some mice remaining disease free for more than 100 days. Thus, anti-CD30 treatment is efficacious for CD30+ ALCL cell lines in vivo, and unconjugated anti-CD30 moAbs may he of potential clinical use.

Original languageEnglish (US)
Pages (from-to)5335-5341
Number of pages7
JournalCancer Research
Volume55
Issue number22
StatePublished - 1995
Externally publishedYes

Fingerprint

Anaplastic Large-Cell Lymphoma
Heterografts
Monoclonal Antibodies
Cell Line
Reed-Sternberg Cells
Ligands
Severe Combined Immunodeficiency
Surface Antigens
Growth
Hodgkin Disease
Cultured Cells
Lymphoma
Cell Survival
Binding Sites
Neoplasm Metastasis
Survival
Brain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tian, Z. G., Longo, D. L., Funakoshi, S., Asai, O., Ferris, D. K., Murphy, W. J., & Murphy, W. J. (1995). In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Research, 55(22), 5335-5341.

In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. / Tian, Z. G.; Longo, D. L.; Funakoshi, S.; Asai, O.; Ferris, D. K.; Murphy, William J; Murphy, W. J.

In: Cancer Research, Vol. 55, No. 22, 1995, p. 5335-5341.

Research output: Contribution to journalArticle

Tian, ZG, Longo, DL, Funakoshi, S, Asai, O, Ferris, DK, Murphy, WJ & Murphy, WJ 1995, 'In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts', Cancer Research, vol. 55, no. 22, pp. 5335-5341.
Tian, Z. G. ; Longo, D. L. ; Funakoshi, S. ; Asai, O. ; Ferris, D. K. ; Murphy, William J ; Murphy, W. J. / In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. In: Cancer Research. 1995 ; Vol. 55, No. 22. pp. 5335-5341.
@article{03a322326fa04383bf64bb9e1b7f8c0e,
title = "In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts",
abstract = "CD30 is a M(r) 120,000 surface antigen identified originally by the Ki-1 monoclonal antibody (rahAb) against primary and cultured Reed-Sternberg cells present in Hodgkin's disease and anaplastic large-cell lymphomas (ALCLs). Examination of two ALCL cell lines (Karpas 299 and Michel) demonstrated cell surface expression of CD30. Incubation of these lymphomas with two anti-CD30 moAbs that recognize the ligand-binding site (M44 or HeFi-1) resulted in significant growth inhibition in vitro, with significant decreases in cell viability. Another anti-CD30 moAb, Ber-H2, which recognizes a determinant not involved in ligand binding, had no effect on ALCL growth in vitro. When these human ALCL lines were transferred i.v. into mice with severe combined immune deficiency, the mice developed extensive metastasis in the s.c., brain, or eye tissues. The treatment of mice with either M44 or HeFi-1 anti-CD30 moAbs resulted in significant increases in survival, with some mice remaining disease free for more than 100 days. Thus, anti-CD30 treatment is efficacious for CD30+ ALCL cell lines in vivo, and unconjugated anti-CD30 moAbs may he of potential clinical use.",
author = "Tian, {Z. G.} and Longo, {D. L.} and S. Funakoshi and O. Asai and Ferris, {D. K.} and Murphy, {William J} and Murphy, {W. J.}",
year = "1995",
language = "English (US)",
volume = "55",
pages = "5335--5341",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts

AU - Tian, Z. G.

AU - Longo, D. L.

AU - Funakoshi, S.

AU - Asai, O.

AU - Ferris, D. K.

AU - Murphy, William J

AU - Murphy, W. J.

PY - 1995

Y1 - 1995

N2 - CD30 is a M(r) 120,000 surface antigen identified originally by the Ki-1 monoclonal antibody (rahAb) against primary and cultured Reed-Sternberg cells present in Hodgkin's disease and anaplastic large-cell lymphomas (ALCLs). Examination of two ALCL cell lines (Karpas 299 and Michel) demonstrated cell surface expression of CD30. Incubation of these lymphomas with two anti-CD30 moAbs that recognize the ligand-binding site (M44 or HeFi-1) resulted in significant growth inhibition in vitro, with significant decreases in cell viability. Another anti-CD30 moAb, Ber-H2, which recognizes a determinant not involved in ligand binding, had no effect on ALCL growth in vitro. When these human ALCL lines were transferred i.v. into mice with severe combined immune deficiency, the mice developed extensive metastasis in the s.c., brain, or eye tissues. The treatment of mice with either M44 or HeFi-1 anti-CD30 moAbs resulted in significant increases in survival, with some mice remaining disease free for more than 100 days. Thus, anti-CD30 treatment is efficacious for CD30+ ALCL cell lines in vivo, and unconjugated anti-CD30 moAbs may he of potential clinical use.

AB - CD30 is a M(r) 120,000 surface antigen identified originally by the Ki-1 monoclonal antibody (rahAb) against primary and cultured Reed-Sternberg cells present in Hodgkin's disease and anaplastic large-cell lymphomas (ALCLs). Examination of two ALCL cell lines (Karpas 299 and Michel) demonstrated cell surface expression of CD30. Incubation of these lymphomas with two anti-CD30 moAbs that recognize the ligand-binding site (M44 or HeFi-1) resulted in significant growth inhibition in vitro, with significant decreases in cell viability. Another anti-CD30 moAb, Ber-H2, which recognizes a determinant not involved in ligand binding, had no effect on ALCL growth in vitro. When these human ALCL lines were transferred i.v. into mice with severe combined immune deficiency, the mice developed extensive metastasis in the s.c., brain, or eye tissues. The treatment of mice with either M44 or HeFi-1 anti-CD30 moAbs resulted in significant increases in survival, with some mice remaining disease free for more than 100 days. Thus, anti-CD30 treatment is efficacious for CD30+ ALCL cell lines in vivo, and unconjugated anti-CD30 moAbs may he of potential clinical use.

UR - http://www.scopus.com/inward/record.url?scp=0028837618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028837618&partnerID=8YFLogxK

M3 - Article

C2 - 7585597

AN - SCOPUS:0028837618

VL - 55

SP - 5335

EP - 5341

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 22

ER -